Korean Circ J.  2010 Jan;40(1):10-15. 10.4070/kcj.2010.40.1.10.

The Effect of Cilostazol on Stent Thrombosis After Drug-Eluting Stent Implantation

• Jeon DS
• Yoo KD
• Park CS
• Shin DI
• Her SH
• Park HJ
• Choi YS
• Kim DB
• Lee CM
• Park CS
• Kim PJ
• Moon KW
• Jang KY
• Kim HY
• Chung WS
• Seung KB
• Kim JH
• Choi KB

• KMID: 1776300
• DOI: http://doi.org/10.4070/kcj.2010.40.1.10

Abstract

BACKGROUND AND OBJECTIVES
Placement of drug-eluting stents (DES) can be complicated by stent thrombosis; prophylactic antiplatelet therapy has been used to prevent such events. We evaluated the efficacy of cilostazol with regard to stent thrombosis as adjunctive antiplatelet therapy. SUBJECTS AND METHODS: A total of 1,315 patients (846 males, 469 females) were prospectively enrolled and analyzed for the frequency of stent thrombosis. Patients with known risk factors for stent thrombosis, except diabetes and acute coronary syndrome, were excluded from the study. All patients maintained antiplatelet therapy for at least six months. To evaluate the effects of cilostazol as another option for antiplatelet therapy, triple antiplatelet therapy (aspirin+clopidogrel+cilostazol, n=502) was compared to dual antiplatelet therapy (aspirin+clopidogrel, n=813). Six months after stent placement, all patients received only two antiplatelet drugs: treatment either with cilostazol+aspirin (cilostazol group) or clopidogrel+aspirin (clopidogrel group). There were 1,033 patients (396 in cilostazol group and 637 in clopidogrel group) that maintained antiplatelet therapy for at least 12 months and were included in this study. Stent thrombosis was defined and classified according to the definition reported by the Academic Research Consortium (ARC). RESULTS: defined and classified according to the definition reported by the Academic Research Consortium (ARC). RESULTS: During follow-up (561.7+/-251.4 days), 15 patients (1.14%) developed stent thrombosis between day 1 to day 657. Stent thrombosis occurred in seven patients (1.39%) on triple antiplatelet therapy and four patients (0.49%) on dual antiplatelet therapy (p=NS) within the first six months after stenting. Six months and later, after stent implantation, one patient (0.25%) developed stent thrombosis in the cilostazol group, and three (0.47%) in the clopidogrel group (p=NS). CONCLUSION: During the first six months after DES triple antiplatelet therapy may be more effective than dual antiplatelet therapy for the prevention of stent thrombosis. However, after the first six months, dual antiplatelet treatment, with aspirin and cilostazol, may have a better cost benefit ratio for the prevention of stent thrombosis.

Keyword

Drug-eluting stents; Cilostazol

MeSH Terms

Acute Coronary Syndrome
Aspirin
Cost-Benefit Analysis
Drug-Eluting Stents
Follow-Up Studies
Humans
Male
Prospective Studies
Risk Factors
Stents
Tetrazoles
Thrombosis
Ticlopidine
Aspirin
Tetrazoles
Ticlopidine

Reference

1. Kim KH, Jeong MH, Hong SN, et al. The clinical effects of drug eluting stents for the treatment of coronary in-stent restenosis. Korean Circ J. 2005. 35:443–447.

2. Yang TH, Hong MK, Park KH, et al. Primary siroliums-eluting stent implantation for patients with acute ST-segment elevation myocardial infarction. Korean Circ J. 2005. 35:672–676.

3. Jeong YS, Cho KH, Park YW, Kim SM, Kim DI, Kim DS. Siroliumus-eluting stent for the treatment of in-stent restenosis: comparison with cutting balloon angioplasty. Korean Circ J. 2006. 36:66–71.

4. Kim DB, Seung KB, Kim BJ, et al. Utilization pattern of drug-eluting stents and prognosis of patients who underwent drug-eluting stenting compared with bare metal stenting in the real world. Korean Circ J. 2006. 36:178–183.

5. Kim BK, Oh SJ, Jeon DW, et al. Clinical outcomes following sirolimus-eluting stent implantation in patients with end-stage renal disease. Korean Circ J. 2006. 36:424–430.

6. Park JS, Kim YJ, Shin DG, et al. Clinical and angiographic outcome of sirolimus-eluting stent for the treatment of very long lesions. Korean Circ J. 2006. 36:490–494.

7. Kim W, Jeong MH, Cho JY, et al. The preventive effect on instent restenosis of overlapped drug-eluting stents for treating diffuse coronary artery disease. Korean Circ J. 2006. 36:17–23.

8. Park DW, Park SW. Stent thrombosis in the era of the drug-eluting stent. Korean Circ J. 2005. 35:791–794.

9. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case of standardized definitions. Circulation. 2007. 115:2344–2351.

10. Park SH, Hong GR, Seo HS, Tahk SJ. Stent thrombosis after successful drug-eluting stent implantation. Korean Circ J. 2005. 35:163–171.

11. Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med. 2005. 353:653–662.

12. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001. 103:1967–1971.

13. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007. 356:1020–1029.

14. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007. 369:667–678.

15. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005. 293:2126–2130.

16. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007. 356:1009–1019.

17. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation. 2007. 115:1440–1455.

18. Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation. 2006. 113:1108–1113.

19. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007. 356:998–1008.

20. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007. 356:1030–1039.

21. Doyle B, Rihal CS, O'Sullivan CJ, et al. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation. 2007. 116:2391–2398.

22. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association task torce on practice guidelines: 2007 writing group to review new evidence and update the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention, writing on behalf of the 2005 writing committee. Circulation. 2008. 117:261–295.

23. Lee SW, Park SW, Hong MK, et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol. 2005. 46:1833–1837.

24. Lee SW, Park SW, Kim YH, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus: the DECLARE-DIABETES trial (a randomized comparison of triple antiplatelet therapy with dual antiplatelet therapy after drug-eluting stent implantation in diabetic patients). J Am Coll Cardiol. 2008. 51:1181–1187.

25. Lee SW, Park SW, Kim YH, et al. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol. 2007. 100:1103–1108.

26. Maeng M, Jensen LO, Kaltoft A, et al. Comparison of stent thrombosis, myocardial infarction, and mortality following drug-eluting versus bare-metal stent coronary intervention in patients with diabetes mellitus. Am J Cardiol. 2008. 102:165–172.